Rep. Lisa C. McClain Purchases Shares of ImmunityBio, Inc. (NASDAQ:IBRX)

Representative Lisa C. McClain (Republican-Michigan) recently bought shares of ImmunityBio, Inc. (NASDAQ:IBRX). In a filing disclosed on October 12th, the Representative disclosed that they had bought between $1,001 and $15,000 in ImmunityBio stock on September 28th. The trade occurred in the Representative’s “CHARLES SCHWAB 401K (HANTZ) > SCHWAB 824” account.

Representative Lisa C. McClain also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 9/30/2026.
• Purchased $1,001 – $15,000 in shares of ImmunityBio (NASDAQ:IBRX) on 9/30/2026.
• Sold $15,001 – $50,000 in shares of Seagate Technology (NASDAQ:STX) on 9/30/2026.
• Purchased $1,001 – $15,000 in shares of Caterpillar (NYSE:CAT) on 9/28/2026.
• Purchased $15,001 – $50,000 in shares of Olin (NYSE:OLN) on 9/14/2026.
• Purchased $1,001 – $15,000 in shares of Novagold Resources (NYSEAMERICAN:NG) on 9/14/2026.
• Purchased $15,001 – $50,000 in shares of Transocean (NYSE:RIG) on 9/14/2026.
• Purchased $15,001 – $50,000 in shares of CACI International (NYSE:CACI) on 9/14/2026.

ImmunityBio Stock Down 3.2%

IBRX stock opened at $9.80 on Wednesday. ImmunityBio, Inc. has a twelve month low of $1.95 and a twelve month high of $12.43. The firm has a market cap of $10.39 billion, a PE ratio of -10.10 and a beta of 0.02. The business has a 50 day moving average of $8.43 and a 200 day moving average of $7.92.

ImmunityBio (NASDAQ:IBRX) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.14). The firm had revenue of $51.24 million during the quarter, compared to analysts’ expectations of $49.70 million. On average, research analysts expect that ImmunityBio, Inc. will post -0.44 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Cheryl Cohen sold 81,056 shares of the company’s stock in a transaction dated Friday, October 2nd. The stock was sold at an average price of $10.50, for a total value of $851,088.00. Following the completion of the transaction, the director owned 100,309 shares of the company’s stock, valued at approximately $1,053,244.50. This represents a 44.69% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Barry J. Simon sold 25,000 shares of ImmunityBio stock in a transaction dated Monday, October 5th. The shares were sold at an average price of $10.75, for a total transaction of $268,750.00. Following the completion of the sale, the director owned 2,777,788 shares in the company, valued at approximately $29,861,221. This trade represents a 0.89% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 66.10% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

IBRX has been the topic of several analyst reports. Jefferies Financial Group raised shares of ImmunityBio to a “strong-buy” rating in a report on Friday, September 25th. Weiss Ratings restated a “sell (d-)” rating on shares of ImmunityBio in a research report on Tuesday, October 6th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $14.20.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Courier Capital LLC grew its position in ImmunityBio by 100.0% during the 3rd quarter. Courier Capital LLC now owns 112,000 shares of the company’s stock worth $1,057,000 after purchasing an additional 56,000 shares during the last quarter. GAMMA Investing LLC lifted its holdings in shares of ImmunityBio by 262.2% during the third quarter. GAMMA Investing LLC now owns 3,807 shares of the company’s stock worth $36,000 after purchasing an additional 2,756 shares during the period. Collective Family Office LLC increased its holdings in ImmunityBio by 2.6% in the 3rd quarter. Collective Family Office LLC now owns 161,254 shares of the company’s stock worth $1,522,000 after buying an additional 4,054 shares during the period. Doliver Advisors LP increased its holdings in ImmunityBio by 110.0% in the 3rd quarter. Doliver Advisors LP now owns 210,000 shares of the company’s stock worth $1,982,000 after buying an additional 110,000 shares during the period. Finally, Envestnet Asset Management Inc. lifted its stake in ImmunityBio by 52.4% during the 2nd quarter. Envestnet Asset Management Inc. now owns 27,659 shares of the company’s stock valued at $242,000 after acquiring an additional 9,513 shares during the period. 8.58% of the stock is owned by institutional investors and hedge funds.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan’s 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.

McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan’s 9th Congressional District. She declared candidacy for the 2026 election.

Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor’s degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

ImmunityBio Company Profile

ImmunityBio, Inc is a biotechnology company focused on developing and commercializing immunotherapies designed to activate and strengthen the body’s immune system against cancer and infectious diseases. The company combines cytokine-based therapies, vaccines, cellular therapies and other immune-modulating technologies in an effort to create durable treatment responses.

Its lead product, ANKTIVA (nogapendekin alfa inbakicept-pmln), is an interleukin-15 receptor agonist immune stimulator.